FDA
-
-
-
-
-
-
-
Coya Therapeutics receives FDA fast track designation for ALS treatment
-
-
-
-
-
-
-
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO
-
-
-
-
-
-
-
Coya Therapeutics CEO outlines 2026 priorities in stockholder letter
-
-
-
-
-
-
-
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
-
-
-
-
-
-
-
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
-
-
-
-
-
-
-
PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies
-
-
-
-
-
-
-
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
-
328,603 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

